---

Marvel drug for infertility!!

---

Original Article

Author Details : Janaki Vellanki, Eppalla Sravani*

Volume : 10, Issue : 4, Year : 2023

Article Page : 456-459

https://doi.org/10.18231/j.ijogr.2023.087

Suggest article by email

Get Permission

---

Abstract

Background: Comparative study of Dydrogesterone versus oral sustained release micronized hydroxy-progesterone for support of luteal phase.
Materials and Methods: A randomized controlled trial, performed from March 2022 to April 2023. 200 women between 18–40 years of age attending infertility OPD at Gandhi hospital were enrolled in this study. Subjects were randomized and were given either oral dydrogesterone or oral sustained release micronized hydroxy-progesterone. Statistical analysis was done accordingly.
Results: In the present study, oral dydrogesterone was demonstrated to be superior than sustained release micronized hydroxy-progesterone, with UPT positive rates being 83% and 30% respectively. Dydrogesterone given orally was tolerated well with similar safety profile to sustained release micronized hydroxy-progesterone.
Conclusion: Our study results depicted the use of dydrogesterone to be effective when compared to oral sustained release micronized hydroxy-progesterone in terms of luteal phase support. Dydrogesterone is hailed to be superior in regards of positive pregnancy rates in the current study.

Keywords: Oral dydrogesterone, Oral sustained release micronized hydroxy-progesterone, Infertility

How to cite : Vellanki J, Sravani E, Marvel drug for infertility!!. Indian J Obstet Gynecol Res 2023;10(4):456-459

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.